The TET3/GATA6 Axis Drives Lipid Metabolism and Therapeutic Vulnerabilities in Pancreatic Ductal Adenocarcinoma. (PubMed, Adv Sci (Weinh)) - Jun 26, 2025 - "Notably, combined treatment with the HDAC inhibitor SAHA and the ferroptosis inducer Erastin significantly enhances gemcitabine-induced cytotoxicity in lipogenic PDAC cells. These findings uncover a previously unrecognized non-catalytic function of TET3 in sustaining lipid metabolic reprogramming in PDAC. Targeting the TET3/GATA6 axis in combination with ferroptosis and epigenetic modulators offers a promising strategy to overcome therapeutic resistance in aggressive pancreatic cancer."
Journal • Metabolic Disorders • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • ACSL3 • GATA6 • SCD • TET3
|
|
Jianxiu Yu; Na Lin; Ruiyu Xie; Shaobo Kang; Shiwen Wang; Shuai Liu; Wenqi Zhang; Xiaofan Ding; Yuqing Ren
|